Lithium Argentina AG (LAR) Stock News

Thor Industries' Board of Directors approved a regular quarterly cash dividend of $0.52 per share, payable on July 15, 2026, to shareholders of record as of July 1, 2026. The company is the world's largest manufacturer of recreational vehicles.

MONTREAL , June 11, 2026 /CNW/ - Dollarama Inc. (TSX: DOL ) ("Dollarama" or the "Corporation") today reported its financial results for the first quarter ended May 3, 2026. Refer to "Selected Segmented Financial Information" on page 6 of this press release for additional information regarding the Corporation's Canadian and Australian reportable segments. Fiscal 2027 First Quarter Results Highlights Compared to Fiscal 2026 First Quarter Sales increased by 21.4% to $1,846.1 million, compared to $1,521.2 million Comparable store sales (1) in Canada increased by 5.6%, compared to 4.9% in the first quarter of the previous year EBITDA (1) increased by 17.4% to $582.5 million, representing an EBITDA margin (1) of 31.6%, compared to 32.6% Operating income increased by 11.2% to $432.2 million, representing an operating margin (1) of 23.4%, compared to 25.6% Net earnings increased by 10.4% to $302.3 million, resulting in a 13.3% increase in diluted net earnings per common share to $1.11, compared to $0.98 Unrealized gain of $16.4 million relating to the derivative on our equity-accounted investments, positively impacting EBITDA margin by 90 basis points and diluted net earnings per common share by $0.06 28 net new stores opened in Canada, compared to 22 in the corresponding period of the previous year; 8 net new stores opened and 13 stores renovated in Australia, all operating under the legacy banner 1,962,010 common shares repurchased for cancellation for $339.1 million "We delivered a strong performance in the first quarter of fiscal 2027 as we pursue profitable growth in our core Canadian market, generating strong comparable store sales growth, expanding our store network and progressing our Western Canada logistics hub project. We are also advancing our priorities across our international growth platforms with discipline. In Latin America, Dollarcity had a solid start to th

Kymera Therapeutics announced preclinical data for KT-579, an oral IRF5 degrader, demonstrating disease-modifying activity in lupus models comparable or superior to approved therapies. The compound showed consistent activity across multiple disease pathways including Type I interferons and pro-inflammatory cytokines. Phase 1 healthy volunteer trial is ongoing with data expected in the second half of 2026, followed by a planned patient proof-of-concept trial in lupus.

Cullinan Therapeutics announced positive Phase 1 clinical data for CLN-978, a CD19xCD3 T cell engager, showing clinical benefit including remissions in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following single target doses. The drug demonstrated deep, dose-dependent B cell depletion with a favorable safety profile. The company will present additional data and host an Immunology Day on June 10 to discuss CLN-978 and initial data for velinotamig, a BCMAxCD3 T cell engager.

Immutep announced positive Phase I interim data for IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The study met its primary endpoint, demonstrating favorable safety and tolerability in healthy volunteers, with statistically significant pharmacodynamic activity at 7 mg/kg dose. The results support further clinical investigation in autoimmune indications such as rheumatoid arthritis.

Tourmaline Oil Corp. announced a quarterly cash dividend of $0.50 per share payable on June 30, 2026, and held its annual shareholder meeting on June 3, 2026, where ten directors were elected. The company is Canada's largest natural gas producer focused on low-cost development in the Western Canadian Sedimentary Basin.

VersaBank (NASDAQ: VBNK) announced a quarterly cash dividend of CAD $0.025 per common share, payable July 31, 2026, to shareholders of record as of July 10, 2026. The dividends are eligible for tax purposes.

Levicept Ltd presented Phase II clinical trial data for LEVI-04, a first-in-class neurotrophin-3 inhibitor for osteoarthritis treatment, at the EULAR conference in London. The study of 518 patients demonstrated significant dose-dependent reductions in bone marrow lesions, clinically meaningful improvements in pain and function comparable to NSAIDs, and a differentiated safety profile compared to anti-NGF therapies.

Zenas BioPharma announced that obexelimab met its primary and all key secondary endpoints in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The drug demonstrated a 56% reduction in flare risk, 65% reduction in glucocorticoid use, and favorable safety profile comparable to placebo. A Biologics License Application (BLA) was submitted to the FDA in May 2026, with results presented at EULAR 2026 Congress and published in the New England Journal of Medicine.

Law firm Bragar Eagel & Squire is investigating Claritev Corporation following a DOJ criminal price-fixing investigation into the company's Data iSight pricing tool, reported by The Capitol Forum on May 14, 2026. The announcement triggered a sharp 41% stock price decline, dropping from $23.47 to $13.87 per share. The firm is seeking stockholders who suffered losses to discuss potential legal claims.

John Hancock Investment Management announced quarterly distributions for four closed-end funds on June 1, 2026. The funds declared distributions ranging from $0.1535 to $0.6500 per share, with payment scheduled for June 30, 2026. Distributions may include net investment income, capital gains, and return of capital.

John Hancock Investment Management announced monthly distributions for its closed-end funds on June 1, 2026. The Tax-Advantaged Dividend Income Fund (HTD) will distribute $0.1580 per share monthly, while the Premium Dividend Fund (PDT) will distribute $0.0825 per share monthly. All distributions are scheduled for payment on June 30, 2026.

Stewart Information Services Corporation (NYSE: STC) announced a cash dividend of $0.525 per share for Q2 2026, payable on June 30, 2026, to shareholders of record as of June 15, 2026. The global real estate services company continues its dividend distribution to common stockholders.

Toronto-Dominion Bank announced a quarterly dividend of $1.12 per common share payable July 31, 2026, to shareholders of record as of July 10, 2026. The bank also declared dividends on three series of preferred shares. Shareholders can participate in the Dividend Reinvestment Plan to have dividends automatically reinvested in additional common shares purchased on the open market.

Flanigan's Enterprises, Inc. (AMEX: BDL), owner and operator of Flanigan's Seafood Bar and Grill restaurants and Big Daddy's retail liquor stores, announced a cash dividend of $0.60 per share to shareholders of record on June 10, 2026, payable on June 26, 2026.

Silvercorp Metals Inc. announced a semi-annual dividend of US$0.0125 per share for shareholders of record as of June 5, 2026, with payment scheduled by June 25, 2026. The dividend is considered eligible for Canadian tax purposes. The company emphasized that future dividend payments will depend on commodity prices, market conditions, financial results, and cash flows.

Braemar Hotels & Resorts Inc. (NYSE: BHR) announced the declaration of monthly preferred dividends across multiple series of preferred stock. The company declared partial cash dividends for Series D, E, and M Redeemable Preferred Stock, with payments scheduled for June and July 2026. As of April 30, 2026, the company had 11.1 million shares of Series E and 1.4 million shares of Series M preferred stock outstanding.

CompX International Inc. (NYSE American: CIX) announced a regular quarterly dividend of $0.30 per share payable on June 16, 2026. At its annual stockholder meeting on May 20, 2026, shareholders elected eight directors for one-year terms and approved executive compensation on a nonbinding advisory basis.

Cullinan Therapeutics announced that initial clinical data from Phase 1 studies of CLN-978, a CD19xCD3 T cell engager, will be presented at EULAR 2026 Congress in June. The data shows favorable safety profiles, robust B cell depletion, and early promising clinical activity in patients with treatment-refractory rheumatoid arthritis and systemic lupus erythematosus.

Old Republic International Corporation announced a regular quarterly dividend of 31.5 cents per share, payable June 15, 2026. The company projects a full-year dividend of $1.26 per share in 2026, representing an 8.6% increase from $1.16 per share in 2025. This marks the 45th consecutive year of dividend increases and the 85th year of uninterrupted dividend payments.

Wyndham Hotels & Resorts (NYSE:WH) announced its Board of Directors declared a quarterly cash dividend of $0.43 per share on common stock, payable June 30, 2026 to shareholders of record as of June 15, 2026. The company operates approximately 8,400 hotels across 100 countries with a portfolio of 25 hotel brands.

KeyCorp announced a quarterly cash dividend of $0.205 per share on common stock payable June 15, 2026, along with dividends on multiple preferred stock series. The company also authorized a new $3.0 billion share repurchase program, replacing its previous $1.0 billion authorization with approximately $280 million remaining.

Hyster-Yale, Inc. (NYSE:HY) announced that its Board of Directors increased the regular cash dividend from 36 cents to 36.5 cents per share. The dividend will be paid on June 16, 2026, to stockholders of record as of June 1, 2026.